ArticleWorld journal of gastroenterology2017
Prognostic value of lymphovascular invasion in Bismuth-Corlette type IV hilar cholangiocarcinoma.
Article in World journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Prediction of lymphovascular invasion in esophageal squamous cell carcinoma by computed tomography-based radiomics analysis: 2D or 3D ?Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Comparison ofAbdominal radiology (New York) · 2023Article
- Prognostic influence for hilar cholangiocarcinoma and comparisons of prognostic values of Mayo staging and TNM staging systems.Medicine · 2022Article
- Predictors for thromboembolism in patients with cholangiocarcinoma.Journal of cancer research and clinical oncology · 2022Article
- Effect of hepatic artery resection and reconstruction on the prognosis of patients with advanced hilar cholangiocarcinoma.World journal of gastrointestinal oncology · 2022Article
- Compelling Long-Term Results for Liver Resection in Early Cholangiocarcinoma.Journal of clinical medicine · 2021Article
- Prognostic impact of lymphovascular invasion in pT1-T3 gallbladder adenocarcinoma.Journal of surgical oncology · 2020Article
- Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma.World journal of gastroenterology · 2020Review
- Lymphocyte to Monocyte Ratio Predicts Resectability and Early Recurrence of Bismuth-Corlette Type IV Hilar Cholangiocarcinoma.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2020Article
- A simple scoring system to predict early recurrence of Bismuth-Corlette type IV perihilar cholangiocarcinoma.Gastroenterology report · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo assess the prognostic value of lymphovascular invasion (LVI) in Bismuth-Corlette type IV hilar cholangiocarcinoma (HC) patients.
methodsA retrospective analysis was performed on 142 consecutively recruited type IV HC patients undergoing radical resection with at least 5 years of follow-up. Survival analysis was performed by the Kaplan-Meier method, and the association between the clinicopathologic variables and survival was evaluated by log-rank test. Multivariate analysis was adopted to identify the independent prognostic factors for overall survival (OS) and disease-free survival (DFS). Multiple logistic regression analysis was performed to determine the association between LVI and potential variables.
resultsLVI was confirmed histopathologically in 29 (20.4%) patients. Multivariate analysis showed that positive resection margin (HR = 6.255, 95%CI: 3.485-11.229,
conclusionLVI is associated with N1 stage and tumor size > 30 mm and adversely influences DFS and OS in type IV HC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.